author-photo

Joyson Joseph Karakunnel

MedImmune

33

Papers

740

Citations

Citation Trend

Filter By

Papers (17) Sort By

Journal Conference Others

AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (12)
Abstract 5045: Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD1 monoclonal antibody, in patients with advanced malignancies

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Abstract A046: Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM)

2016 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (0)
57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC.

2016 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (85)
Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma

2015 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (12)
Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status

2015 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (10)
418OPhase 1b study of the safety and antitumour activity of durvalumab (MEDI4736) + tremelimumab in advanced NSCLC

2015 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Pharmacokinetics and pharmacodynamics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in combination with tremelimumab in patients with advanced non-small cell lung cancer (NSCLC).

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (36)